Predictive Biomarkers in Nephrology Around the Corner

Affiliations

¹ Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
² Center for Renal Precision Medicine, Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.

Editorial

Paul Perco et al. Kidney Int Rep. 2019.

. 2019 Nov 2;5(1):1-3.

doi: 10.1016/j.ekir.2019.10.009. eCollection 2020 Jan.

¹ Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
² Center for Renal Precision Medicine, Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.

No abstract available

Comment on

Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics.
Agrawal S, Merchant ML, Kino J, Li M, Wilkey DW, Gaweda AE, Brier ME, Chanley MA, Gooding JR, Sumner SJ, Klein JB, Smoyer WE; Midwest Pediatric Nephrology Consortium. Agrawal S, et al. Kidney Int Rep. 2019 Sep 19;5(1):66-80. doi: 10.1016/j.ekir.2019.09.009. eCollection 2020 Jan. Kidney Int Rep. 2019. PMID: 31922062 Free PMC article.
Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Metabolomics.
Gooding JR, Agrawal S, McRitchie S, Acuff Z, Merchant ML, Klein JB, Smoyer WE, Sumner SJ; Midwest Pediatric Nephrology Consortium. Gooding JR, et al. Kidney Int Rep. 2019 Sep 19;5(1):81-93. doi: 10.1016/j.ekir.2019.09.010. eCollection 2020 Jan. Kidney Int Rep. 2019. PMID: 31922063 Free PMC article.

1. Perkovic V., Jardine M.J., Neal B. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. - PubMed
1. Mayer B., Heinzel A., Lukas A. Predictive biomarkers for linking disease pathology and drug effect. Curr Pharm Des. 2017;23:29–54. - PubMed
1. Heerspink H.J.L., Perco P., Mulder S. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62:1154–1166. - PMC - PubMed
1. Mulder S., Heerspink H.J.L., Darshi M. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes Obes Metab. 2019;21:2422–2428. - PubMed
1. Sharma K., Karl B., Mathew A.V. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24:1901–1912. - PMC - PubMed